Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) Equity Average (2022 - 2025)

Bioregenx has reported Equity Average over the past 4 years, most recently at -$4.1 million for Q4 2025.

  • For Q4 2025, Equity Average fell 180.38% year-over-year to -$4.1 million; the TTM value through Dec 2025 reached -$4.1 million, down 180.38%, while the annual FY2025 figure was -$4.0 million, 45.24% down from the prior year.
  • Equity Average for Q4 2025 was -$4.1 million at Bioregenx, down from -$3.7 million in the prior quarter.
  • Over five years, Equity Average peaked at $14.7 million in Q2 2024 and troughed at -$4.1 million in Q4 2025.
  • A 4-year average of $838217.5 and a median of -$1.9 million in 2022 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: plummeted 2560.67% in 2023 and later soared 686.61% in 2024.
  • Year by year, Equity Average stood at -$1.4 million in 2022, then crashed by 78.76% to -$2.4 million in 2023, then soared by 309.09% to $5.1 million in 2024, then crashed by 180.38% to -$4.1 million in 2025.
  • Business Quant data shows Equity Average for BRGX at -$4.1 million in Q4 2025, -$3.7 million in Q3 2025, and -$3.6 million in Q2 2025.